Antiproliferative and apoptotic effects of paeonol on human hepatocellular carcinoma cells

Anti-Cancer Drugs

Volumn 19, Issue 4, 2008, Pages 401-409

  Chunhu, Zhang ^a   Suiyu, Hu ^a   Meiqun, Cao ^a   Guilin, Xiao ^a   Yunhui, Li ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

AKT; Apoptosis; Cancer therapy; Human hepatocarcinoma cell; Paeonol; PTEN

Indexed keywords

CELL DNA; FLUOROURACIL; MESSENGER RNA; PEONOL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; ACETOPHENONE DERIVATIVE; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOASSAY; CANCER INHIBITION; CARCINOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; CELL PROLIFERATION; DOSE RESPONSE; LIVER TUMOR; METABOLISM; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACETOPHENONES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLUOROURACIL; HUMANS; LIVER NEOPLASMS;

EID: 47949127978     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282f7f4eb     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-156.
2. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005; 19:3-23.
3. Johnson PJ. Hepatocellular carcinoma: is current therapy really altering outcome? Gut 2002; 51:459-462.
4. Tan S, Ye J, Qian C, Ji C, Liu C, Wang J. Paeonol inhibits the proliferation of human colorectal carcinoma cells and synergic with chemotherapeutic agents. Saudi Med J 2007; 28:642-643.
5. Chou TC. Anti-inflammatory and analgesic effects of paeonol in carrageenan-evoked thermal hyperalgesia. Br J Pharmacol 2003; 139:1146-1152.
6. Mi XJ, Chen SW, Wang WJ, Wang R, Zhang YJ, Li WJ, et al. Anxiolytic-like effect of paeonol in mice. Pharmacol Biochem Behav 2005; 81:683-687.
7. Stoll V, Calleja V, Vassaux G, Downward J, Lemoine NR. Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer. Gut 2005; 54:109-116.
8. Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous Cell carcinoma. Int J Cancer 2005; 114:242-248.
9. Kohno T, Takahashi M, Manda R, Yokota J. Inactivation of the PTEN/MMAC1/ TEP1 gene in human lung cancers. Genes Chromosomes Cancer 1998; 22:152-156.
10. Okami K, Wu L, Riggins G, Cairns P, Goggins M, Evron E, et al. Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res 1998; 58:509-511.
11. Osaki M, Oshimura M, Ito H. PI3K-AKT pathway: its functions and alterations in human cancer. Apoptosis 2004; 9:667-676.
12. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI3-kinase/AKT signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 2004; 23:8571-8580.
13. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
14. Tada H, Shiho O, Kuroshima K, Koyama M, Tsukamoto K. An improved colorimetric assay for interleukin 2. J Immunol Methods 1986; 93:157-165.
15. Clifford MN. Diet-derived phenols in plasma and tissues and their implications for health. Planta Med 2004; 70:1103-1114.
16. Cao SS, Zhen YS. Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol 1989; 24:181-186.
17. Vadgama JV, Wu Y, Shen D, Hsia S, Block J. Effect of selenium in combination with adriamycin or taxol on several different cancer cells. Anticancer Res 2000; 20:1391-1414.
18. Staal SP. Molecular cloning of the akt Oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A 1987; 84:5034-5037.
19. Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997; 57:2124-2129.
20. Downward J. Mechanisms and consequences of activation of protein kinase B/AKT. Curr Opin Cell Biol 1998; 10:262-267.
21. Konishi H, Kuroda S, Tanaka M, Matsuzaki H, Ono Y, Kameyama K, et al. Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. Biochem Biophys Res Commun 1995; 216: 526-534.
22. Adey NB, Huang L, Ormonde PA, Baumgard ML, Pero R, Byreddy DV, et al. Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding. Cancer Res 2000; 60:35-47.
23. Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 2001; 276: 48627-48630.
24. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, et al. Phosphorylation of AKT (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004; 64:5232-5236.
25. Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 2004; 54:385-390.
26. Yin XY, Lu MD, Liang LJ, Lai JM, Li DM, Kuang M. Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma. World J Gastroenterol 2005; 11:2526-2529.
27. Sun GP, Wang H, Shen YX, Zhai ZM, Wei W, Xu SY. Study on effects of paeonol in inhibiting growth of K562 and inducing its apoptosis. Zhongguo Yaolixie Tongbao 2004; 20:550-552.
28. Tolkacheva T, Boddapati M, Sanfiz A, Tsuchida K, Kimmelman AC, Chan AM. Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res 2001; 61:4985-4989.
29. Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, Hanafusa H. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res 2000; 60:7033-7038.
30. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/ AKT pathway. Proc Natl Acad Sci U S A 1999; 96:4240-4245.
31. Damelin LH, Vokes S, Whitcutt JM, Damelin SB, Alexander JJ. Hormesis: a stress response in cells exposed to low levels of heavy metals. Hum Exp Toxicol 2000; 19:420-430.